{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:51:38Z","timestamp":1774569098603,"version":"3.50.1"},"reference-count":35,"publisher":"Scientific Scholar","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Palliat Care"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijpc.ijpc_233_19","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T13:54:19Z","timestamp":1605880459000},"page":"506","source":"Crossref","is-referenced-by-count":6,"title":["Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among multiple myeloma patients: A single-center experience"],"prefix":"10.25259","volume":"26","author":[{"given":"NailaA","family":"Shaheen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NadaS","family":"Alawbthani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Alaskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0973-1075.300805-1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: A critical analysis","author":"Park","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0973-1075.300805-2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.5603\/GP.2016.0036","article-title":"Chemotherapy-induced peripheral neuropathy \u2013 Diagnosis, evolution and treatment","author":"I\u017cycki","year":"2016","journal-title":"Ginekol Pol"},{"key":"key-10.4103\/0973-1075.300805-3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale","author":"Cavaletti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"key":"key-10.4103\/0973-1075.300805-4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","article-title":"Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity","author":"Cavaletti,","year":"2006","journal-title":"J Peripher Nerv Syst"},{"key":"key-10.4103\/0973-1075.300805-5","first-page":"797","article-title":"Cancer pain and its impact on diagnosis, survival and quality of life.Nature Reviews","author":"Mantyh","year":"2006","journal-title":"Neuroscience"},{"key":"key-10.4103\/0973-1075.300805-6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): An update","author":"Argyriou,","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"key-10.4103\/0973-1075.300805-7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3892\/br.2017.851","article-title":"Chemotherapy-induced peripheral neuropathy","author":"Zhang","year":"2017","journal-title":"Biomed Rep"},{"key":"key-10.4103\/0973-1075.300805-8","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"key-10.4103\/0973-1075.300805-9","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1075.300805-10","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"key-10.4103\/0973-1075.300805-11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11912-007-0036-x","article-title":"Chemotherapy-induced neuropathy","author":"Bhagra","year":"2007","journal-title":"Curr Oncol Rep"},{"key":"key-10.4103\/0973-1075.300805-12","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3324\/haematol.11752","article-title":"Bortezomib-induced peripheral neurotoxicity: Still far from a painless gain","author":"Cavaletti,","year":"2007","journal-title":"Haematologica"},{"key":"key-10.4103\/0973-1075.300805-13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy","author":"Hausheer","year":"2006","journal-title":"Semin Oncol"},{"key":"key-10.4103\/0973-1075.300805-14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0213-4853(10)70036-0","article-title":"Chemotherapy-induced peripheral neuropathy: An unresolved issue","author":"Velasco","year":"2010","journal-title":"Neurologia"},{"key":"key-10.4103\/0973-1075.300805-15","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature","author":"Argyriou,","year":"2008","journal-title":"Blood"},{"key":"key-10.4103\/0973-1075.300805-16","first-page":"435","article-title":"Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents","author":"Argyriou","year":"2010","journal-title":"J BUON"},{"key":"key-10.4103\/0973-1075.300805-17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00839140","article-title":"Cisplatin neuropathy: Clinical course and neurophysiological findings","author":"LoMonaco","year":"1992","journal-title":"J Neurol"},{"key":"key-10.4103\/0973-1075.300805-18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy","author":"Windebank","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"key-10.4103\/0973-1075.300805-19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1745-7599.2004.tb00458.x","article-title":"Clinical evaluation and patterns of chemotherapy-induced peripheral neuropathy","author":"Visovsky","year":"2004","journal-title":"J Am Acad Nurse Pract"},{"key":"key-10.4103\/0973-1075.300805-20","first-page":"W9","article-title":"The modified total neuropathy score: A clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer","author":"Wampler","year":"2006","journal-title":"J Support Oncol"},{"key":"key-10.4103\/0973-1075.300805-21","first-page":"2767","article-title":"Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy","author":"da","year":"2014","journal-title":"Support Care Cancer"},{"key":"key-10.4103\/0973-1075.300805-22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","article-title":"Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"key-10.4103\/0973-1075.300805-23","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2012.44.8738","article-title":"Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy","author":"Hershman","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1075.300805-24","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0973-1075.300805-25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1188\/11.CJON.182-188","article-title":"Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin","author":"Tofthagen","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"key-10.4103\/0973-1075.300805-26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1075.300805-27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00520-011-1141-9","article-title":"The relationship between numbness, tingling, and shooting\/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA","author":"Wolf","year":"2012","journal-title":"Support Care Cancer"},{"key":"key-10.4103\/0973-1075.300805-28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","article-title":"Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy","author":"Chaudhry","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"key-10.4103\/0973-1075.300805-29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study","author":"Dimopoulos","year":"2011","journal-title":"Eur J Haematol"},{"key":"key-10.4103\/0973-1075.300805-30","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00520-015-3032-y","article-title":"Chemotherapy-induced neuropathy in multiple myeloma: Influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice","author":"Beijers","year":"2016","journal-title":"Support Care Cancer"},{"key":"key-10.4103\/0973-1075.300805-31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-1331.2010.03220.x","article-title":"Screening for tumours in paraneoplastic syndromes: Report of an EFNS task force","author":"Titulaer","year":"2011","journal-title":"Eur J Neurol"},{"key":"key-10.4103\/0973-1075.300805-32","doi-asserted-by":"crossref","unstructured":"Gado\u00f3 K, Domja\u00e1n G. Quality of Life Issues of Patients with Multiple Myeloma. Ch. 14. London, UK: IntechOpen; 2013.","DOI":"10.5772\/55625"},{"key":"key-10.4103\/0973-1075.300805-33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: Results from a population-based study using the PROFILES registry","author":"Mols","year":"2012","journal-title":"Eur J Haematol"},{"key":"key-10.4103\/0973-1075.300805-34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5388\/jkon.2010.10.2.231","article-title":"Characteristics and quality of life in patients with chemotherapy-induced peripheral neuropathy","author":"Kwak","year":"2010","journal-title":"J Korean Oncol Nurs"},{"key":"key-10.4103\/0973-1075.300805-35","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.leu.2403723","article-title":"Severe irreversible bilateral hearing loss after bortezomib (VELCADE\u00ae) therapy in a multiple myeloma (MM) patient","author":"Engelhardt","year":"2005","journal-title":"Leukemia"}],"container-title":["Indian Journal of Palliative Care"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T06:51:09Z","timestamp":1691218269000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpalliativecare.com\/chemotherapy-induced-peripheral-neuropathy-and-its-impact-on-health-related-quality-of-life-among-multiple-myeloma-patients-a-single-center-experience\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"alternative-id":["300805"],"URL":"https:\/\/doi.org\/10.4103\/ijpc.ijpc_233_19","relation":{},"ISSN":["0973-1075"],"issn-type":[{"value":"0973-1075","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}